LIGHTPATH TECHNOLOGIES INC
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
LPTH$7.99-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Equity
Condensed Consolidated Statements of Changes in Stockholders' Equity
| Temporary Equity · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Series G Convertible · Class A · Additional · Other · Total | ||||||||
| Preferred Stock · Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||||
| Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |
| Balances at June 30, 2025 | 24,956 | $34,232,510 | 42,949,307 | $429,493 | $244,953,346 | $978,686 | $(230,716,757) | $15,644,768 |
| Issuance of common stock for: | ||||||||
| Exercise of stock options, RSUs & RSAs, net | — | — | 8,583 | 86 | (86) | — | — | — |
| Issuance of common stock under private equity placement | — | — | 1,600,000 | 16,000 | 7,878,045 | — | — | 7,894,045 |
| Issuance of common stock for acquisition of Visimid | — | — | 112,323 | 1,123 | 348,877 | — | — | 350,000 |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | — | — | 349,624 | — | — | 349,624 |
| Foreign currency translation adjustment | — | — | — | — | — | 92,383 | — | 92,383 |
| Net loss | — | — | — | — | — | — | (2,893,002) | (2,893,002) |
| Balances at September 30, 2025 | 24,956 | $34,232,510 | 44,670,213 | $446,702 | $253,529,806 | $1,071,069 | $(233,609,759) | $21,437,818 |
| Issuance of common stock for: | ||||||||
| Exercise of stock options, RSUs & RSAs, net | — | — | 120,234 | 1,203 | (1,203) | — | — | — |
| Exercise of warrants | — | — | 739,730 | 7,397 | (7,397) | — | — | — |
| Issuance of common stock under public equity placement | — | — | 8,912,500 | 89,125 | 65,251,709 | — | — | 65,340,834 |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | — | — | 348,986 | — | — | 348,986 |
| Foreign currency translation adjustment | — | — | — | — | — | 212,859 | — | 212,859 |
| Net loss | — | — | — | — | — | — | (9,405,409) | (9,405,409) |
| Balances at December 31, 2025 | 24,956 | $34,232,510 | 54,442,677 | $544,427 | $319,121,901 | $1,283,928 | $(243,015,168) | $77,935,088 |
| Issuance of common stock for: | ||||||||
| Employee Stock Purchase Plan | — | — | 2,302 | 23 | 24,839 | — | — | 24,862 |
| Exercise of stock options, RSUs & RSAs, net | — | — | 112,723 | 1,127 | 11,376 | — | — | 12,503 |
| Exercise of warrants | — | — | 2,728,968 | 27,290 | (27,290) | — | — | — |
| Fees for issuance of common stock under public equity placement | — | — | — | — | (98,293) | — | — | (98,293) |
| Issuance of common stock for acquisition of Amorphous | — | — | 83,518 | 835 | 1,026,245 | — | — | 1,027,080 |
| Issuance of common stock for acquisition of G5 | — | — | 297,445 | 2,974 | 3,146,968 | — | — | 3,149,942 |
| Conversion of Series G Preferred to Common | (7,610) | (10,438,326) | 3,539,379 | 35,394 | 10,402,932 | — | — | 10,438,326 |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | — | — | 704,717 | — | — | 704,717 |
| Foreign currency translation adjustment | — | — | — | — | — | 1,739 | — | 1,739 |
| Net loss | — | — | — | — | — | — | (4,106,287) | (4,106,287) |
| Balances at March 31, 2026 | 17,346 | $23,794,184 | 61,207,012 | $612,070 | $334,313,395 | $1,285,667 | $(247,121,455) | $89,089,677 |
| Balances at June 30, 2024 | — | $— | 39,254,643 | $392,546 | $245,140,758 | $509,936 | $(215,843,575) | $30,199,665 |
| Issuance of common stock for: | ||||||||
| Employee Stock Purchase Plan | — | — | 8,232 | 82 | 10,290 | — | — | 10,372 |
| Exercise of Stock Options, RSUs & RSAs, net | — | — | 70,309 | 703 | (703) | — | — | — |
| Issuance of common stock for acquisition of Visimid | — | — | 279,553 | 2,796 | 318,562 | — | — | 321,358 |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | — | — | 264,475 | — | — | 264,475 |
| Foreign currency translation adjustment | — | — | — | — | — | 271,594 | — | 271,594 |
| Net loss | — | — | — | — | — | — | (1,622,745) | (1,622,745) |
| Balances at September 30, 2024 | — | $— | 39,612,737 | $396,127 | $245,733,382 | $781,530 | $(217,466,320) | $29,444,719 |
| Issuance of common stock for: | ||||||||
| Exercise of Stock Options, RSUs & RSAs, net | — | — | 229,097 | 2,291 | (2,291) | — | — | — |
| Shares issued as compensation | — | — | 49,000 | 490 | 89,180 | — | — | 89,670 |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | — | — | 231,581 | — | — | 231,581 |
| Foreign currency translation adjustment | — | — | — | — | — | (451,035) | — | (451,035) |
| Net loss | — | — | — | — | — | — | (2,611,997) | (2,611,997) |
| Balances at December 31, 2024 | — | $— | 39,890,834 | $398,908 | $246,051,852 | $330,495 | $(220,078,317) | $26,702,938 |
| Issuance of preferred stock under private equity placement, net of fees | 24,956 | 19,648,488 | — | — | — | — | — | — |
| Issuance of common stock for: | ||||||||
| Employee Stock Purchase Plan | — | — | 1,137 | 11 | 4,002 | — | — | 4,013 |
| Exercise of Stock Options, RSUs & RSAs, net | — | — | 238,641 | 2,387 | 788 | — | — | 3,175 |
| Issuance of common stock for acquisition of Visimid | — | — | 102,700 | 1,027 | 391,561 | — | — | 392,588 |
| Issuance of common stock for acquisition of G5 | — | — | 1,972,501 | 19,725 | 4,852,343 | — | — | 4,872,068 |
| Issuance of common stock under private equity placement, net of fees | — | — | 687,750 | 6,878 | 1,584,014 | — | — | 1,590,892 |
| Issuance of warrants under private placement, net of fees | — | — | — | — | 177,445 | — | — | 177,445 |
| Preferred cumulative dividends plus accretion | — | 14,751,134 | — | — | (14,751,134) | — | — | (14,751,134) |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | — | — | 194,303 | — | — | 194,303 |
| Foreign currency translation adjustment | — | — | — | — | — | 120,572 | — | 120,572 |
| Net loss | — | — | — | — | — | — | (3,582,460) | (3,582,460) |
| Balances at March 31, 2025 | 24,956 | $34,399,622 | 42,893,563 | $428,936 | $238,505,174 | $451,067 | $(223,660,777) | $15,724,400 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.